Levi & Korsinsky Investigates Neogen After FDA Warning
Law firm Levi & Korsinsky has launched an investigation into Neogen Corporation following a U.S. Food and Drug Administration (FDA) warning concerning the company's HYCOAT equine product, which led to a significant stock price drop.
Law firm Levi & Korsinsky is investigating Neogen Corporation after a U.S. Food and Drug Administration (FDA) warning regarding the company's HYCOAT equine product caused Neogen's stock to plummet by as much as 7.22% in a single trading session.
The investigation will examine whether Neogen adequately informed investors of product quality risks associated with HYCOAT before the news became public. FDA testing reportedly identified multiple fungal species in the product, which was marketed as sterile. Reports indicate nearly 100 horses were affected and at least 20 have died.
The stock decline occurred prior to any earnings report. Levi & Korsinsky is looking into potential securities law violations on behalf of Neogen shareholders who have suffered losses. Investors who lost money are encouraged to contact the law firm.
Neogen Corporation, a producer of animal safety products, has not yet commented on the ongoing investigation. The company's next quarterly earnings report is scheduled for October 6, 2026.